Risk of breakthrough infection and hospitalisation after COVID-19 primary vaccination by HIV status in four Italian regions during 2021

被引:0
作者
Mateo-Urdiales, Alberto [1 ]
Fabiani, Massimo [1 ]
Mayer, Flavia [2 ]
Sacco, Chiara [1 ,3 ]
Belleudi, Valeria [4 ]
Da Cas, Roberto [2 ]
Fotakis, Emmanouil Alexandros [1 ,3 ]
De Angelis, Luigi [5 ]
Cutillo, Maria [2 ]
Petrone, Daniele [1 ]
Morciano, Cristina [2 ]
Cannone, Andrea [1 ]
Del Manso, Martina [1 ]
Riccardo, Flavia [1 ]
Bella, Antonino [1 ]
Menniti-Ippolito, Franscesca [2 ]
Pezzotti, Patrizio [1 ]
Alegiani, Stefania Spila [2 ]
Massari, Marco [2 ]
机构
[1] Ist Super Sanita, Dept Infect Dis, Rome, Italy
[2] Ist Super Sanita, Natl Ctr Drug Res & Evaluat, Rome, Italy
[3] European Ctr Dis Prevent & Control, European Programme Intervent Epidemiol Training EP, Stockholm, Sweden
[4] ASL Roma 1, Dept Epidemiol, Lazio Reg Hlth Serv, Rome, Italy
[5] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
关键词
HIV; COVID-19; VACCINES; AIDS; MULTICENTER;
D O I
10.1186/s12889-024-19071-y
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background As of 2024, vaccination remains the main mitigation measure against COVID-19, but there are contradictory results on whether people living with HIV (PLWH) are less protected by vaccines than people living without HIV (PLWoH). In this study we compared the risk of SARS-CoV-2 infection and COVID-19 hospitalisation following full vaccination in PLWH and PLWoH.Methods We linked data from the vaccination registry, the COVID-19 surveillance system and from healthcare/pharmacological registries in four Italian regions. We identified PLWH fully vaccinated (14 days post completion of the primary cycle) and matched them at a ratio of 1:4 with PLWoH by week of vaccine administration, age, sex, region of residence and comorbidities. Follow-up started on January 24, 2021, and lasted for a maximum of 234 days. We used the Kaplan-Meier estimator to calculate the cumulative incidence of infection and COVID-19 hospitalisation in both groups, and we compared risks using risk differences and ratios taking PLWoH as the reference group.Results We matched 42,771 PLWH with 171,084 PLWoH. The overall risk of breakthrough infection was similar in both groups with a rate ratio (RR) of 1.10 (95% confidence interval (CI):0.80-1.53). The absolute difference between groups at the end of the study period was 8.28 events per 10,000 person-days in the PLWH group (95%CI:-18.43-40.29). There was a non-significant increase the risk of COVID-19 hospitalisation among PLWH (RR:1.90; 95%CI:0.93-3.32) which corresponds to 6.73 hospitalisations per 10,000 individuals (95%CI: -0.57 to 14.87 per 10,000).Conclusions Our findings suggest PLWH were not at increased risk of breakthrough SARS-CoV-2 infection or COVID-19 hospitalisation following a primary cycle of mRNA vaccination.
引用
收藏
页数:9
相关论文
共 40 条
[1]  
Agenzia Italiana del Farmaco, Vaccini COVID-19
[2]   Postmarketing observational study on the safety of 2021/2022 and 2022/2023 influenza vaccination campaigns in Italy: TheShinISS-Vax|Flu study protocol [J].
Alegiani, Stefania Spila ;
Morciano, Cristina ;
Menniti-Ippolito, Francesca ;
Da Cas, Roberto ;
Felicetti, Patrizia ;
Marchione, Pasquale ;
Petronzelli, Fiorella ;
Marra, Anna Rosa ;
Massari, Marco .
BMJ OPEN, 2023, 13 (08)
[3]  
[Anonymous], 2018, The R Project for Statistical Computing
[4]   Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count [J].
Antinori, Andrea ;
Cicalini, Stefania ;
Meschi, Silvia ;
Bordoni, Veronica ;
Lorenzini, Patrizia ;
Vergori, Alessandra ;
Lanini, Simone ;
De Pascale, Lidya ;
Matusali, Giulia ;
Mariotti, Davide ;
Lepri, Alessandro Cozzi ;
Galli, Paola ;
Pinnetti, Carmela ;
Gagliardini, Roberta ;
Mazzotta, Valentina ;
Mastrorosa, Ilaria ;
Grisetti, Susanna ;
Colavita, Francesca ;
Cimini, Eleonora ;
Grilli, Elisabetta ;
Bellagamba, Rita ;
Lapa, Daniele ;
Sacchi, Alessandra ;
Marani, Alessandra ;
Cerini, Carlo ;
Candela, Caterina ;
Fusto, Marisa ;
Puro, Vincenzo ;
Castilletti, Concetta ;
Agrati, Chiara ;
Girardi, Enrico ;
Vaia, Francesco .
CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) :E552-E563
[5]   Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J].
Baden, Lindsey R. ;
El Sahly, Hana M. ;
Essink, Brandon ;
Kotloff, Karen ;
Frey, Sharon ;
Novak, Rick ;
Diemert, David ;
Spector, Stephen A. ;
Rouphael, Nadine ;
Creech, C. Buddy ;
McGettigan, John ;
Khetan, Shishir ;
Segall, Nathan ;
Solis, Joel ;
Brosz, Adam ;
Fierro, Carlos ;
Schwartz, Howard ;
Neuzil, Kathleen ;
Corey, Larry ;
Gilbert, Peter ;
Janes, Holly ;
Follmann, Dean ;
Marovich, Mary ;
Mascola, John ;
Polakowski, Laura ;
Ledgerwood, Julie ;
Graham, Barney S. ;
Bennett, Hamilton ;
Pajon, Rolando ;
Knightly, Conor ;
Leav, Brett ;
Deng, Weiping ;
Zhou, Honghong ;
Han, Shu ;
Ivarsson, Melanie ;
Miller, Jacqueline ;
Zaks, Tal .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :403-416
[6]   An Italian multicentre distributed data research network to study the use, effectiveness, and safety of immunosuppressive drugs in transplant patients: Framework and perspectives of the CESIT project [J].
Belleudi, Valeria ;
Rosa, Alessandro C. ;
Finocchietti, Marco ;
Poggi, Francesca R. ;
Marino, Maria Lucia ;
Massari, Marco ;
Alegiani, Stefania Spila ;
Masiero, Lucia ;
Ricci, Andrea ;
Bedeschi, Gaia ;
Puoti, Francesca ;
Cardillo, Massimo ;
Pierobon, Silvia ;
Nordio, Maurizio ;
Ferroni, Eliana ;
Zanforlini, Martina ;
Piccolo, Giuseppe ;
Leone, Olivia ;
Ledda, Stefano ;
Carta, Paolo ;
Garau, Donatella ;
Lucenteforte, Ersilia ;
Davoli, Marina ;
Addis, Antonio .
FRONTIERS IN PHARMACOLOGY, 2022, 13
[7]   Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients [J].
Bertrand, Dominique ;
Hamzaoui, Mouad ;
Lemee, Veronique ;
Lamulle, Julie ;
Hanoy, Melanie ;
Laurent, Charlotte ;
Lebourg, Ludivine ;
Etienne, Isabelle ;
Lemoine, Mathilde ;
Le Roy, Frank ;
Nezam, Dorian ;
Plantier, Jean-Christophe ;
Boyer, Olivier ;
Guerrot, Dominique ;
Candon, Sophie .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (09) :2148-2153
[8]   Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination [J].
Butt, Adeel A. ;
Khan, Tasnim ;
Yan, Peng ;
Shaikh, Obaid S. ;
Omer, Saad B. ;
Mayr, Florian .
JOURNAL OF INFECTION, 2021, 83 (02) :246-247
[9]   People diagnosed with HIV and in care in Italy in 2014: results from the second national survey [J].
Camoni, Laura ;
Raimondo, Mariangela ;
Urciuoli, Roberta ;
Iacchini, Simone ;
Suligoi, Barbara ;
Pezzotti, Patrizio .
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2018, 30 (06) :760-764
[10]   Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States [J].
Coburn, Sally B. ;
Humes, Elizabeth ;
Lang, Raynell ;
Stewart, Cameron ;
Hogan, Brenna C. ;
Gebo, Kelly A. ;
Napravnik, Sonia ;
Edwards, Jessie K. ;
Browne, Lindsay E. ;
Park, Lesley S. ;
Justice, Amy C. ;
Gordon, Kirsha S. ;
Horberg, Michael A. ;
Certa, Julia M. ;
Watson, Eric ;
Jefferson, Celeena R. ;
Silverberg, Michael J. ;
Skarbinski, Jacek ;
Leyden, Wendy A. ;
Williams, Carolyn F. ;
Althoff, Keri N. .
JAMA NETWORK OPEN, 2022, 5 (06) :E2215934